King’s Lynn doctors awarded prestigious NHS England Fellowship for Innovation


09-07-2015

Healthcare pioneers receive national support to roll out innovative technologies to patients, hospitals and GP practices throughout England.

 

Health Enterprise East (HEE), the leading NHS Innovation Hub for the East of England, East Midlands and North London, congratulates Drs Maryanne Mariyaselvam and Peter Young of Queen Elizabeth Hospitals King’s Lynn (QEHKL), on becoming fellows of the NHS Innovation Accelerator (NIA) programme.

The scheme, announced on Monday by Sir Bruce Keogh, NHS England’s Medical Director, sets out to get evidenced healthcare innovations adopted at scale and pace nationally, ultimately making them more widely available to patients. QEHKL is a HEE Member Trust; both Dr Mariyaselvam’s and Dr Young’s technologies were originally progressed with support of HEE which has assisted with the development of both projects to date.

Dr Mariyaselvam and Dr Young join a prestigious group of 17 healthcare pioneers from the UK and abroad identified to receive national support to roll out their technologies, processes and models of care to patients, hospitals and GP practices throughout England. Through the fellowship, each will receive mentorship from seasoned innovators such as Lord Ara Darzi, a bursary, and support to spread these new ways of working across the country.

Dr Mariyaselvam’s innovation, the Non-Injectable Arterial Connector (NIC), will improve the safety and care of all patients requiring an arterial line in operating theatres and intensive care.

Dr Young’s innovation, the PneuX Pneumonia Prevention System, is designed to stop ventilator-associated pneumonia (VAP), the leading cause of hospital-acquired mortality in intensive care units.

In a joint comment, Drs Mariyaselvam and Young said: "Innovation should be at the heart of the NHS, as should mechanisms for spreading innovative solutions to patients quickly and effectively. We are delighted that both technologies have been selected for the NIA programme and with the support of NHS England, we look forward to seeing them scaled and implemented nationally across the NHS. As a Member Trust, QEHKL is thankful to HEE for its help in the development of the projects to date and in reaching this significant milestone."

“This is great news from one of our Members' Trusts and we pass on our sincerest congratulations to Maryanne and Peter on being awarded NIA fellowships,” commented Stuart Thomson, Commercialisation Director, HEE. “Having worked closely with the inventors, clinical team and QEH on these and other projects, we are delighted that both innovations will be receiving NHS England support for national roll out in order to deliver significant and wide reaching patient benefit.”

For more information visit www.hee.org.uk

About Health Enterprise East

Health Enterprise East Limited (HEE) is the NHS Innovation Hub for the East of England, East Midlands and North London. We are committed to improving healthcare through supporting the development of innovative new products and services which meet the needs of the NHS. HEE provides a broad range of services to NHS organisations, providing expert advice, funding and support to NHS innovators to translate their ideas into practice.

Operating within the NHS, HEE also provides consultancy services to technology-based companies looking to access the UK market. We work with clinical key opinion leaders and senior NHS managerial, commissioning and procurement staff on a daily basis. Our NHS market assessments provide vital information for companies to ensure that their products are well targeted to the technical and business needs of the NHS, speeding up adoption of new technology by the NHS.

About the NHS Innovation Accelerator (NIA) Programme

The aim of the NHS Innovation Accelerator (NIA) programme is to help deliver on the commitment detailed within the Five Year Forward View – understanding how to create the conditions and cultural change necessary for proven innovations to be adopted faster and more systematically through the NHS, and to deliver examples into practice for demonstrable patient and population benefit.

The programme is hosted by UCLPartners and the Health Foundation, in partnership with NHS England and in collaboration with Academic Health Science Networks across the country. The delivery teams will to work together with patient groups to develop future strategies for innovation where diffusion is planned from the outset with patients and local communities.

More than 120 people from the UK and internationally applied to join the programme. They included experienced innovation diffusers, leaders, founders and representatives of high impact innovative products, services, technologies and care models. Through the rigorous application process, innovators needed to demonstrate a passion and commitment for taking their innovations forward at scale.

The programme will support a broad portfolio of innovations including: devices; healthcare applications; new models of care; online resources and technology platforms covering the clinical areas of cancer, mental health, multiple sclerosis, maternity care, cardiovascular disease, respiratory disease, liver disease and dementia.

About Dr Maryanne Mariyaselvam

Dr Maryanne Mariyaselvam is Clinical Research Fellow at the Queen Elizabeth Hospital, King’s Lynn and Addenbrooke’s University Hospital, Cambridge. She is currently undertaking a Doctorate at the University of Cambridge relating to Patient Safety in the NHS and is specifically researching the use of innovation to prevent never events or serious adverse events.

Maryanne’s innovation is the Non-injectable arterial connector (NIC), which improves the safety and care of all patients requiring an arterial line in operating theatres and intensive care. Although rare, when wrong route drug administration occurs, it has the potential to cause serious damage to the vessel and surrounding tissue. The NIC enables conventional arterial line sampling, but eradicates the potential to accidentally administer medication into the arterial line and is a definitive solution to the problem.

The NIC has been trialled by 11 trusts in the East of England and Maryanne hopes to implement the NIC nationally through the NIA programme.

About Dr Peter Young

Dr Peter Young is a proven innovator having developed ten devices, three of which have been brought to market. His innovation on the NIA programme is the PneuX Pneumonia Prevention System, which is designed to stop ventilator-associated pneumonia (VAP), the leading cause of hospital-acquired mortality in Intensive Care Units. The innovation is a cuffed ventilation tube and an electronic cuff monitoring and inflating device which prevents leakage of bacterial laden oral and stomach contents to the lung – a problem associated with standard tubes.

Peter says his experience has shown that coming up with the idea is not the challenge but scaling a great innovation across the NHS involves many challenges. His ambition for the NIA is to overcome the barriers to diffusion.

Peter is Consultant in Anesthesia and Director of Critical Care at the Queen Elizabeth Hospital, King’s Lynn.

*******

Contacts:

Health Enterprise East
 Chris Armstrong
 Email: chris.armstrong@hee.co.uk
 Phone: +44 (0) 1223 597813

Media contact
Sarah Jeffery
Zyme Communications
 E-mail: sarah.jeffery@zymecommunications.com
 Phone: +44 (0) 7771 730919
_____________________________________________

 

Health Enterprise East (HEE) delivers technology advisory and innovation management services to industry and the NHS.

Health Enterprise East